Log In


Improving heart failure outcomes: EMPEROR-Reduced trial

Watch Professor Andrew Coats and Professor Faiez Zannad as they discuss key findings from the EMPEROR-Reduced Phase III trial, which looks at the association between empagliflozin and improved cardiovascular outcomes in heart failure patients with reduced ejection fraction (HFrEF), with and without diabetes.


The EMPEROR-Reduced trial is a phase III randomised, double-blind trial that aims to evaluate the efficacy and safety of empagliflozin compared with placebo in patients with chronic heart failure with HFrEF, with and without diabetes mellitus (DM). This 30-minute journal club will explore the insights and impact of the recent primary endpoint results of the EMPEROR-Reduced trial presented at the European Society of Cardiology (ESC) Congress 2020.

Target audience

This educational activity is designed for cardiologists, surgeons, primary care physicians, GPs, nurses and any other healthcare professional with an interest or role in heart failure management.

Learning objectives

  • Describe the mechanism of action of empagliflozin and its therapeutic value in the management of cardio-renal-metabolic conditions
  • Recall why empagliflozin is effective in reducing mortality risk in heart failure patients, with and without DM2
  • Explain the impact of empagliflozin on hospitalisation rates for heart failure patients, with and without DM2


An accreditation application has been submitted for this Journal Club to the Royal College of Physicians (RCP) and is currently under review.


Professor Andrew Coats
University of Warwick, UK
Professor of Cardiology at the University of Warwick, UK and President of the Heart Failure Association at the European Society of Cardiology
Professor Faiez Zannad
Université of Lorraine, France
Professor Emeritus of Therapeutics at the Université of Lorraine, France and section editor of the European Society of Cardiology (ESC) Textbook

Want to access this as a module?

Missed a live event? All journal club recordings can be accessed here to explore or revisit in your own time via our eLearning platform.